{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:28:51Z","timestamp":1786638531277,"version":"build-2736575974"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Hyponatremia is an adverse event associated with antipsychotic use; however, comparative evidence among individual second-generation antipsychotics remains limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the risk of hyponatremia associated with individual second-generation antipsychotics.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n In this retrospective cohort study and disproportionality analysis, data were obtained from the US Food and Drug Administration Adverse Event Reporting System (FAERS; quarter 4 1997 to quarter 3 2023), a dataset provided by the Japan Pharmaceutical Information Center, and a Japanese hospital-based claims database (Medical Data Vision; April 2008 to April 2024). The study adopted a new-user design and included patients routinely prescribed antipsychotics. Patients aged 18 to 69 years with at least 180 days of active medical history preceding the initial antipsychotic prescription, with no history of antipsychotics or hyponatremia during that period, were included.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Initiation of second-generation antipsychotics.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Hyponatremia associated with individual antipsychotics was compared with that associated with olanzapine. Reporting odds ratios with 95% CIs were calculated for FAERS. The incidence within 180 days of treatment initiation was analyzed for claims database using hazard ratios estimated with stabilized inverse probability of treatment weighting based on propensity scores.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In the FAERS database, most antipsychotics showed lower reporting odds ratios for hyponatremia than olanzapine. In a Japanese claims database, among 961 010 patients prescribed antipsychotics, 55 394 were included in the final analysis. The mean (SD) age was 50.4 (14.3) years, and there were 25 839 (46.6%) male and 29 555 (53.4%) female patients. After stabilized inverse probability of treatment weighting, aripiprazole was associated with a significantly lower risk of hyponatremia than olanzapine (adjusted hazard ratio, 0.52; 95% CI, 0.35-0.76), whereas other antipsychotics showed no significant differences. Sensitivity analysis confirmed the robustness of the findings.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this retrospective cohort study of antipsychotic users, aripiprazole was associated with a lower risk of hyponatremia than was olanzapine. Although residual confounding should be considered, these findings may help inform clinical decision-making for high-risk patients.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.28796","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:30:32Z","timestamp":1786635032000},"page":"e2628796","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Risk of Hyponatremia Among Patients Treated With Second-Generation Antipsychotics"],"prefix":"10.1001","volume":"9","author":[{"given":"Masakazu","family":"Hatano","sequence":"first","affiliation":[{"name":"Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenao","family":"Koseki","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake, Japan"},{"name":"Department of Advanced Medical Professional Development, Fujita Health University Graduate School of Medical Sciences, Toyoake, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"issue":"1","key":"zoi260783r1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41537-021-00192-x","article-title":"Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics.","volume":"8","author":"Correll","year":"2022","journal-title":"Schizophrenia (Heidelb)"},{"issue":"9831","key":"zoi260783r2","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"zoi260783r3","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41380-021-01334-4","article-title":"Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.","volume":"27","author":"Kishi","year":"2022","journal-title":"Mol Psychiatry"},{"issue":"1","key":"zoi260783r4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12888-025-06783-7","article-title":"The augmentative efficacy of second-generation anti-psychotics (SGA) to anti-depressants in treating treatment-resistant depression: a network meta-regression analysis.","volume":"25","author":"Bai","year":"2025","journal-title":"BMC Psychiatry"},{"issue":"2","key":"zoi260783r5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2165\/11319070-000000000-00000","article-title":"Antipsychotic-induced hyponatraemia: a systematic review of the published evidence.","volume":"33","author":"Meulendijks","year":"2010","journal-title":"Drug Saf"},{"issue":"16","key":"zoi260783r6","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1056\/NEJMcp2210411","article-title":"The syndrome of inappropriate antidiuresis.","volume":"389","author":"Adrogu\u00e9","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi260783r7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/ijnp\/pyab005","article-title":"Hyponatremia following antipsychotic treatment: in silico pharmacodynamics analysis of spontaneous reports from the US Food and Drug Administration Adverse Event Reporting System database and an updated systematic review.","volume":"24","author":"Mazhar","year":"2021","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"zoi260783r8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.psychres.2012.01.022","article-title":"Medical outcome of psychiatric inpatients with admission hyponatremia.","volume":"198","author":"Manu","year":"2012","journal-title":"Psychiatry Res"},{"issue":"6","key":"zoi260783r9","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/JCP.0b013e3182a4736f","article-title":"Epidemiology, symptoms, and treatment characteristics of hyponatremic psychiatric inpatients.","volume":"33","author":"Lange-Asschenfeldt","year":"2013","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"zoi260783r10","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1001\/jama.2022.11176","article-title":"Diagnosis and management of hyponatremia: a review.","volume":"328","author":"Adrogu\u00e9","year":"2022","journal-title":"JAMA"},{"issue":"18","key":"zoi260783r11","doi-asserted-by":"publisher","first-page":"6584","DOI":"10.3390\/jcm14186584","article-title":"Drug-induced hyponatremia: insights into pharmacological mechanisms and clinical practice management.","volume":"14","author":"Capinha","year":"2025","journal-title":"J Clin Med"},{"key":"zoi260783r12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejim.2025.04.034","article-title":"Drug-induced hyponatremia in clinical care.","volume":"137","author":"Mannheimer","year":"2025","journal-title":"Eur J Intern Med"},{"issue":"6","key":"zoi260783r13","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source.","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief Bioinform"},{"key":"zoi260783r14","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems.","volume":"3","author":"Cutroneo","year":"2024","journal-title":"Front Drug Saf Regul"},{"issue":"10","key":"zoi260783r15","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2183\/pjab.98.026","article-title":"Clinical epidemiology and pharmacoepidemiology studies with real-world databases.","volume":"98","author":"Yoshida","year":"2022","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"9","key":"zoi260783r16","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s40264-025-01548-3","article-title":"Interplay of spontaneous reporting and longitudinal healthcare databases for signal management: position statement from the real-world evidence and big data special interest group of the International Society of pharmacovigilance.","volume":"48","author":"Crisafulli","year":"2025","journal-title":"Drug Saf"},{"issue":"6","key":"zoi260783r17","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): development and statement.","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"zoi260783r18","doi-asserted-by":"publisher","first-page":"k3532","DOI":"10.1136\/bmj.k3532","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE).","volume":"363","author":"Langan","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"zoi260783r19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions.","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"zoi260783r20","doi-asserted-by":"publisher","first-page":"398","DOI":"10.7326\/M18-3079","article-title":"Graphical depiction of longitudinal study designs in health care databases.","volume":"170","author":"Schneeweiss","year":"2019","journal-title":"Ann Intern Med"},{"key":"zoi260783r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2021.110654","article-title":"Management of SIADH-related hyponatremia due to psychotropic medications: an expert consensus from the Association of Medicine and Psychiatry.","volume":"151","author":"Pinkhasov","year":"2021","journal-title":"J Psychosom Res"},{"issue":"28","key":"zoi260783r22","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"issue":"3","key":"zoi260783r23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies.","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"7","key":"zoi260783r24","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2165\/11532560-000000000-00000","article-title":"Hyponatraemia as an adverse drug reaction of antipsychotic drugs: a case-control study in VigiBase.","volume":"33","author":"Mannesse","year":"2010","journal-title":"Drug Saf"},{"key":"zoi260783r25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40697-016-0111-z","article-title":"Atypical antipsychotic medications and hyponatremia in older adults: a population-based cohort study.","volume":"3","author":"Gandhi","year":"2016","journal-title":"Can J Kidney Health Dis"},{"issue":"5","key":"zoi260783r26","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00213-017-4525-9","article-title":"Antipsychotic use is a risk factor for hyponatremia in patients with schizophrenia: a 15-year follow-up study.","volume":"234","author":"Yang","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"zoi260783r27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejim.2018.11.011","article-title":"Antipsychotics and severe hyponatremia: a Swedish population-based case-control study.","volume":"60","author":"Falhammar","year":"2019","journal-title":"Eur J Intern Med"},{"issue":"7","key":"zoi260783r28","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1176\/ajp.155.7.921","article-title":"5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.","volume":"155","author":"Kapur","year":"1998","journal-title":"Am J Psychiatry"},{"key":"zoi260783r29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.euroneuro.2025.07.011","article-title":"Comparative receptor pharmacology of antipsychotic drugs based on normalized binding affinity data and breadth of interaction.","volume":"99","author":"Lange-Asschenfeldt","year":"2025","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"zoi260783r30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine.","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"zoi260783r31","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1080\/00016357.2023.2166105","article-title":"High anticholinergic burden and hyposalivation and xerostomia in the elderly.","volume":"81","author":"Stenb\u00e4ck","year":"2023","journal-title":"Acta Odontol Scand"},{"issue":"8","key":"zoi260783r32","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1111\/odi.15337","article-title":"Oral adverse effects of antipsychotic medications: a case\/noncase analysis of EudraVigilance data.","volume":"31","author":"Urien","year":"2025","journal-title":"Oral Dis"},{"issue":"1","key":"zoi260783r33","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.","volume":"302","author":"Burris","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"zoi260783r34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2217\/cer.14.53","article-title":"Revisiting the washout period in the incident user study design: why 6-12 months may not be sufficient.","volume":"4","author":"Roberts","year":"2015","journal-title":"J Comp Eff Res"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2852735\/hatano_2026_oi_260783_1785962765.31446.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:30:33Z","timestamp":1786635033000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2852735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.28796","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]}}}